Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Amphastar reported financial results for the three months ended June 30, 2026.
Amphastar Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Amphastar reported financial results for the three months ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the quarter’s detailed financial results
- Results are furnished, not filed under Exchange Act Section 18 liability standards
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $183.9M, up 5%; gross margin improved to 50.8% from 49.6%, supported by higher-margin launches
- GAAP net income $30.3M, down from $31.0M; diluted EPS increased to $0.67 from $0.64 on fewer shares
- Ipratropium bromide generated $8.4M after its April 2026 launch; iron sucrose and teriparatide also strengthened product diversification
- BAQSIMI sales fell 3% amid pricing pressure; $175.0M annual sales milestone triggers a $100.0M Lilly payment in Q3 2026
- Glucagon revenue declined 42% and epinephrine faced competition, highlighting ongoing pricing and portfolio-mix risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amphastar Pharmaceuticals, Inc. 8-K filings
Get the next AMPH 8-K as it lands
Follow AMPH for push alerts, or ask the research agent what this filing means.